BBV154 (nasal covid vaccine) has received approval for phase-3 clinical trials. The trials will evaluate BBV154 nasal vaccine for both the two-dose primary schedule and booster dose schedule, the sources said. An intra-nasal vaccine would not only be simple to administer but also reduce the use of needles and syringes, among others. It would also impact the overall cost of a vaccination drive, chairman of Bharat Biotech Krishna Ella had said.
Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said. However, this doesn't mean the two COVID-19 vaccines will be available at shops soon though people would be able to buy them from hospitals and clinics, sources have said. Key details are awaited from the government, they said.